TY - JOUR
T1 - Changes in C-reactive protein from low-fat diet and/or physical activity in men and women with and without metabolic syndrome
AU - Camhi, Sarah M.
AU - Stefanick, Marcia L.
AU - Ridker, Paul M.
AU - Young, Deborah Rohm
N1 - Funding Information:
Supported by funds from the National Institutes of Health grant R21 HL086651. The authors responsibilities were as follows: Sarah M Camhi—CRP data collection, statistical analysis, results interpretation, manuscript drafting; Deborah R Young—analysis, results interpretation, manuscript drafting; Marcia L Stefanick—study design, data collection supervision, results interpretation, manuscript revisions; Paul M Ridker—results interpretation, manuscript revisions, advice, and consultation.
Funding Information:
Dr Ridker reports having received research funding support from multiple not-for-profit entities including the National Heart, Lung, and Blood Institute; the National Cancer Institute; the American Heart Association; the Doris Duke Charitable Foundation; the Leducq Foundation; the Donald W Reynolds Foundation; and the James and Polly Annenberg La Vea Charitable Trusts. Dr Ridker also reports having received investigator-initiated research support from multiple for-profit entities including Astra-Zeneca, Novartis, Pharmacia, Roche, Sanofi-Aventis, and Abbott, as well as nonfinancial research support from Amgen. Dr Ridker is listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to Seimens and AstraZemeca, and has served as a research consultant to Schering-Plough, Sanofi/Aventis, AstraZeneca, Isis, Dade, Merck, Novartis, and Vascular Biogenics.
PY - 2010/1
Y1 - 2010/1
N2 - Change in high-sensitivity C-reactive protein (CRP) from low-fat diet (diet) and physical activity (PA) interventions is relatively unknown for adults with metabolic syndrome. The objective of the study was to assess CRP change (ΔCRP) with diet and/or PA in men and women with and without metabolic syndrome. Men (n = 149) and postmenopausal women (n = 125) with elevated low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol were recruited into a 1-year randomized controlled trial. Treatment groups were as follows: control, diet (reduced total fat, saturated fat, and cholesterol intake), PA (45-60 minutes at 60%-85% maximum heart rate), or diet + PA. Weight loss was not an intervention focus. Metabolic syndrome was defined using the American Heart Association/National Heart, Lung, and Blood Institute criteria. Stored plasma samples were analyzed for CRP. Change in CRP was compared between treatments, within sex and metabolic syndrome status, using analysis of covariance, including covariates for baseline CRP and body fat change. For women with metabolic syndrome (n = 39), ΔCRP was greater in diet vs control (-1.2 ± 0.4, P = .009), diet + PA vs control (-1.3 ± 0.4, P = .006), and diet + PA vs PA (-1.1 ± 0.4, P = .02). Women with metabolic syndrome receiving the diet component (diet or diet + PA) had greater ΔCRP compared with those who did not (control or PA) (P = .001). Change in CRP was not significantly different between intervention groups in men overall, women overall, men with (n = 47) or without metabolic syndrome (n = 102), or women without metabolic syndrome (n = 86). Low-fat diet may be the most effective treatment for reducing CRP in women with metabolic syndrome.
AB - Change in high-sensitivity C-reactive protein (CRP) from low-fat diet (diet) and physical activity (PA) interventions is relatively unknown for adults with metabolic syndrome. The objective of the study was to assess CRP change (ΔCRP) with diet and/or PA in men and women with and without metabolic syndrome. Men (n = 149) and postmenopausal women (n = 125) with elevated low-density lipoprotein cholesterol and low high-density lipoprotein cholesterol were recruited into a 1-year randomized controlled trial. Treatment groups were as follows: control, diet (reduced total fat, saturated fat, and cholesterol intake), PA (45-60 minutes at 60%-85% maximum heart rate), or diet + PA. Weight loss was not an intervention focus. Metabolic syndrome was defined using the American Heart Association/National Heart, Lung, and Blood Institute criteria. Stored plasma samples were analyzed for CRP. Change in CRP was compared between treatments, within sex and metabolic syndrome status, using analysis of covariance, including covariates for baseline CRP and body fat change. For women with metabolic syndrome (n = 39), ΔCRP was greater in diet vs control (-1.2 ± 0.4, P = .009), diet + PA vs control (-1.3 ± 0.4, P = .006), and diet + PA vs PA (-1.1 ± 0.4, P = .02). Women with metabolic syndrome receiving the diet component (diet or diet + PA) had greater ΔCRP compared with those who did not (control or PA) (P = .001). Change in CRP was not significantly different between intervention groups in men overall, women overall, men with (n = 47) or without metabolic syndrome (n = 102), or women without metabolic syndrome (n = 86). Low-fat diet may be the most effective treatment for reducing CRP in women with metabolic syndrome.
UR - http://www.scopus.com/inward/record.url?scp=72149123418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72149123418&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2009.07.008
DO - 10.1016/j.metabol.2009.07.008
M3 - Article
C2 - 19709693
AN - SCOPUS:72149123418
SN - 0026-0495
VL - 59
SP - 54
EP - 61
JO - Metabolism: clinical and experimental
JF - Metabolism: clinical and experimental
IS - 1
ER -